LIFECOME BIOCHEMISTRY CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.98 CNY | +1.42% |
|
+0.60% | -29.54% |
| 2023 | Lifecome Biochemistry Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| 2023 | Lifecome Biochemistry Co.,Ltd.(XSEC:002868) added to S&P Global BMI Index | CI |
| Sales 2021 | 363M 50.15M | Sales 2022 | 330M 45.52M | Capitalization | 8.14B 1.12B |
|---|---|---|---|---|---|
| Net income 2021 | -26M -3.59M | Net income 2022 | -122M -16.84M | EV / Sales 2021 | 5.19 x |
| Net Debt 2021 | 193M 26.65M | Net Debt 2022 | 372M 51.32M | EV / Sales 2022 | 25.8 x |
| P/E ratio 2021 |
-64.9
x | P/E ratio 2022 |
-67.2
x | Employees | 788 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 28.17% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.42% | ||
| 1 week | +0.60% | ||
| Current month | -15.37% | ||
| 1 month | -18.41% | ||
| 3 months | -25.03% | ||
| 6 months | -40.53% | ||
| Current year | -29.54% |
1 week
14.52
15.10
1 month
13.8618.70
Current year
13.5233.00
1 year
13.5240.87
3 years
9.0065.90
5 years
9.0065.90
10 years
9.0065.90
| Managers | Title | Age | Since |
|---|---|---|---|
Tan Ping Lai
CEO | Chief Executive Officer | 60 | 09-11-30 |
Zhong Shou Bao
DFI | Director of Finance/CFO | 54 | 12-05-27 |
Qiu Xian Zheng
CTO | Chief Tech/Sci/R&D Officer | 70 | 12-05-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tan Ping Lai
CEO | Chief Executive Officer | 60 | 09-11-30 |
Wei Min Zhang
PRN | Corporate Officer/Principal | 65 | 03-05-31 |
Zhen Wu Feng
CHM | Chairman | 59 | 06-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 14.98 | +1.42% | 1,588,659 |
| 24-04-25 | 14.77 | +0.89% | 1,317,600 |
| 24-04-24 | 14.64 | -1.35% | 1,306,695 |
| 24-04-23 | 14.84 | +0.20% | 1,136,600 |
| 24-04-22 | 14.81 | -0.54% | 1,153,600 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
LIFECOME BIOCHEMISTRY CO LTD is a China-based company principally engaged in the development, production and sales of veterinary drugs. The Company's businesses include the production and sales of veterinary premixes, veterinary raw materials, veterinary soluble powders, food additives, feed additives and biological pesticide. Its products include bacitracin products, colistin sulfate products, flavomycin products, natamycin, Bacillus subtilis, Bacillus licheniformis, mixed probiotics, Bacillus thuringiensis series and Jinggangmycin series. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -29.54% | 317M | |
| -19.73% | 72.39B | |
| -11.01% | 6.54B | |
| +15.88% | 3.43B | |
| -1.67% | 3.12B | |
| +0.84% | 1.4B | |
| -17.27% | 1.34B | |
| -4.20% | 1.26B | |
| -28.16% | 1.2B | |
| -14.67% | 1.12B |
- Stock Market
- Equities
- 002868 Stock
